Krsnaa Diagnostics Announces Investor Conference Call on November 10, 2025
Krsnaa Diagnostics Limited announces a conference call to discuss the results for the quarter and half-year ended September 30, 2025, scheduled for November 10, 2025, at 10:00 Hrs (IST).
The announcement provides information about an upcoming conference call, which is relevant to investors and could influence their perception of the company's performance.
The announcement is purely informational, detailing the schedule of an investor call, with no inherent positive or negative implications.
* Krsnaa Diagnostics Limited has scheduled a Post Earnings Conference Call on Monday, November 10, 2025, at 10:00 Hrs (IST). * The call will begin with a brief management discussion on the results for the quarter and half-year ended September 30, 2025, followed by an interactive Q&A session. * The transcript and audio link of the call will be available on the company's website. * Mr. Rajendra Mutha (Chairman & Whole-time Director), Mr. Yash Mutha (Managing Director), Ms. Pallavi Bhatevara (Executive Director), Mr. Mitesh Dave (Group CEO), Mr. Pawan Daga (Chief Financial Officer), and Mr. Vivek Jain (Head Investor Relations) will be the speakers on the call.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.